The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

The CDC ACIP recommends 2 doses of the 2024-2025 COVID-19 vaccine for those age 65+ years and 2 or more doses for immunocompromised individuals.

Lung ultrasound (LUS) may be an effective screening tool for interstitial lung disease in patients with asymptomatic rheumatoid arthritis.

A gap persists between the need for and receipt of substance use disorder treatment among United States individuals.

Coffee drinking timing is associated with all-cause and cardiovascular disease-specific mortality risk, according to study findings.

Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist.

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

One in four older US veterans report being diagnosed with cardiovascular disease in their lifetime, according to study findings.

About three-quarters of adolescents report common mental disorders, with a high likelihood of chronicity of symptoms.

V116 (PCV21) was more cost-effective than PCV20 alone and PCV15 plus PPSV23 for the prevention of adult pneumococcal disease.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Evidence is lacking to support integration for improving the value of health care, according to study findings.